Comparison of the Effect of Vitamin K2 and Risedronate on Trabecular Bone in Glucocorticoid-Treated Rats: A Bone Histomorphometry Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To compare the effect of vitamin K2 and risedronate on trabecular bone in glucocorticoid (GC)-treated rats. Materials and Methods: Forty-eight Sprague-Dawley female rats, 3 months of age, were randomized by the stratified weight method into 5 groups according to the following treatment schedule: age-matched control, GC administration, and GC administration with concomitant administration of vitamin K2, risedronate, or vitamin K2 + risedronate. GC (methylprednisolone sodium succinate, 5.0 mg/kg) and risedronate (10 μg/kg) were administered subcutaneously three and five times a week, respectively. Vitamin K2 (menatetrenone, 30 mg/kg) was administered orally three times a week. At the end of the 8-week experiment, bone histomorphometric analysis was performed on trabecular bone of the tibial proximal metaphysis. Results: GC administration decreased trabecular bone mass compared with age-matched controls because of decreased bone formation (mineralizing surface, mineral apposition rate, and bone formation rate) and increased bone erosion. Vitamin K2 attenuated GC-induced trabecular bone loss by preventing GC-induced decrease in bone formation (mineralizing surface) and subsequently reducing GC-induced increase in bone erosion. Risedronate prevented GC-induced trabecular bone loss by preventing GC-induced increase in bone erosion although it also suppressed bone formation (mineralizing surface, mineral apposition rate, and bone formation rate). Vitamin K2 mildly attenuated suppression of bone formation (mineralizing surface) and bone erosion caused by risedronate without affecting trabecular bone mass when administered in combination. Conclusion: The present study showed differential effect of vitamin K2 and risedronate on trabecular bone in GC-treated rats.
Abstract
Purpose: To compare the effect of vitamin K2 and risedronate on trabecular bone in glucocorticoid (GC)-treated rats. Materials and Methods: Forty-eight Sprague-Dawley female rats, 3 months of age, were randomized by the stratified weight method into 5 groups according to the following treatment schedule: age-matched control, GC administration, and GC administration with concomitant administration of vitamin K2, risedronate, or vitamin K2 + risedronate. GC (methylprednisolone sodium succinate, 5.0 mg/kg) and risedronate (10 μg/kg) were administered subcutaneously three and five times a week, respectively. Vitamin K2 (menatetrenone, 30 mg/kg) was administered orally three times a week. At the end of the 8-week experiment, bone histomorphometric analysis was performed on trabecular bone of the tibial proximal metaphysis. Results: GC administration decreased trabecular bone mass compared with age-matched controls because of decreased bone formation (mineralizing surface, mineral apposition rate, and bone formation rate) and increased bone erosion. Vitamin K2 attenuated GC-induced trabecular bone loss by preventing GC-induced decrease in bone formation (mineralizing surface) and subsequently reducing GC-induced increase in bone erosion. Risedronate prevented GC-induced trabecular bone loss by preventing GC-induced increase in bone erosion although it also suppressed bone formation (mineralizing surface, mineral apposition rate, and bone formation rate). Vitamin K2 mildly attenuated suppression of bone formation (mineralizing surface) and bone erosion caused by risedronate without affecting trabecular bone mass when administered in combination. Conclusion: The present study showed differential effect of vitamin K2 and risedronate on trabecular bone in GC-treated rats.
참고문헌 (32)
- Longui CA, "Glucocorticoid therapy: minimizing side effects", J Pediatr (Rio J), 83(5), pp.S163~S177 (2007)
- Van Staa TP, "The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis", Osteoporos Int, 13, pp.777~787 (2002)
- Van Staa TP, "Use of oral corticosteroids and risk of fractures", J Bone Miner Res, 15, pp.993~1000 (2000)
- Nawata H, "Guidelines on the management and treatment of glucocorticoidinduced osteoporosis of the Japanese Society for Bone and Mineral Research", J Bone Miner Metab, 23, pp.105~109 (2005)
- Wallach S, "Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy", Calcif Tissue Int, 67, pp.277~285 (2000)
- Reid DM, "Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study", Bone Miner Res, 15, pp.1006~1013 (2000)
- Tanaka I, "Vitamin K2 as a potential therapeutic agent for glucocorticoid-induced osteoporosis", Clin Calcium, 17, pp.1738~1744 (2007)
- Balooch G, "The aminobisphosphonate risedronate preserves localized mineral and material properties of bone in the presence of glucocorticoids", Arthritis Rheum, 56, pp.3726~3737 (2007)
- Iwamoto J, "Preventive effects of risedronate and calcitriol on cancellous osteopenia in rats treated with high-dose glucocorticoid", Exp Anim, 55, pp.349~355 (2006)
- Hara K, "Vitamin K2 (menatetrenone) inhibits bone loss induced by prednisolone partly through enhancement of bone formation in rats", Bone, 31, pp.575~581 (2002)
- Iwamoto J, "Effect of vitamin K2 on cortical and cancellous bones in orchidectomized and", or sciatic neurectomized rats, 2003, pp.18, 776~783
- Iwamoto J, "Comparative effects of risedronate and calcitriol on cancellous bone in rats with glucocorticoid-induced osteopenia", J Nutr Sci Vitaminol (Tokyo), 52, pp.21~27 (2006)
- Erben RG, "Embedding of bone samples in methylmethacrylate: an improved method suitable for bone histomorphometry, histochemistry, and immunohistochemistry", Histochem Cytochem, 45, pp.307~313 (1997)
- Parfitt AM, "Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee", J Bone Miner Res, 2, pp.595~610 (1987)
- Prakasam G, "Effects of growth hormone and testosterone on cortical bone formation and bone density in aged orchiectomized rats", Bone, 24, pp.491~497 (1999)
- Shen V, "Prednisolone alone, or in combination with estrogen or dietary calcium deficiency or immobilization, inhibits bone formation but does not induce bone loss in mature rats", Biol, 21, pp.345~351 (1997)
- Furuichi H, "Bone-anabolic effect of salmon calcitonin on glucocorticoidinduced osteopenia in rats", Bio Pharm Bull, 23, pp.946~951 (2000)
- Nitta T, "Glucocorticoid-induced secondary osteopenia in female rats: a time course study as compared with ovariectomy-induced osteopenia and response to salmon calcitonin", Jpn J Pharmacol, 79, pp.379~386 (1999)
- Noa M, "Effect of D-003, a mixture of very high molecular weight aliphatic acids, on prednisolone- induced osteoporosis in Sprague-Dawley rats", Drugs R D, 5, pp.281~290 (2004)
- Tanaka Y, "Effects of a synthetic vitamin D analog, ED-71, on bone dynamics and strength in cancellous and cortical bone in prednisolone-treated rats", J Bone Miner Res, 11, pp.325~336 (1996)
- Manolagas SC, "New developments in the pathogenesis and treatment of steroid-induced osteoporosis", J Bone Miner Res, 14, pp.1061~1066 (1999)
- Hauschka PV, "Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone", Physiol Rev, 69, pp.990~1047 (1989)
- Koshihara Y, "Vitamin K2 enhances osteocalcin accumulation in the extracellular matrix of human osteoblasts in vitro", J Bone Miner Res, 12, pp.431~438 (1997)
- Shearer MJ, "Vitamin K", Lancet, 345, pp.229~234 (1995)
- Vermeer C, "Role of vitamin K in bone metabolism", Annu Rev Nutr, 15, pp.1~22 (1995)
- Tabb MM, "Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR", J Biol Chem, 278, pp.43919~43927 (2003)
- Rogers MJ, "Molecular mechanisms of action of bisphosphonate", Bone, 24(5), pp.S73~S79 (1999)
- Iwamoto J, "Effects of vitamin K2 on the development of osteopenia in rats as the models of osteoporosis", Yonsei Med J, 47, pp.157~166 (2006)
- Ito M, "Bone mass, microstructure, and quality with bone strength - The effects of antiresorptive agents -", J Jpn Soc Bone Morphom, 12, pp.51~54 (2002)
- Otomo H, "Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2", J Bone Miner Metab, 22, pp.404~414 (2004)
- Iwasaki Y, "Combination use of vitamin K(2) further increases bone volume and ameliorates extremely low turnover bone induced by bisphosphonate therapy in tail-suspension rats", J Bone Miner Me, 21, pp.154~160 (2003)
- NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, "Osteoporosis prevention, diagnosis, and therapy", JAMA, 285, pp.785~795 (2001)